Perspective: A Novel Prognostic for Sickle Cell Disease

Sickle hemoglobin (α2βS2) polymerization drives disease pathophysiology in sickle cell anemia. Fetal hemoglobin (α2γ2) restricts disease severity by inhibiting the polymerization of sickle hemoglobin in a concentration-dependent manner. Clinical decision-making relies on diagnostic technologies evaluating fetal hemoglobin as mean percent or mean quantity in blood. Limitation of this approach is exemplified by patients with significant high fetal hemoglobin levels and severe disease, suggesting that fetal hemoglobin is unevenly distributed across F-cells. Therefore, determination of fetal hemoglobin/F-cell would provide a new paradigm for ascertaining prognosis and response to fetal hemoglobin-inducing agents. Measurement of fetal hemoglobin/F-cell, ultimately adapted to widespread standardized analytical use, is a promising fetal hemoglobin-related prognostic approach to monitor the severity of sickle cell disease and the best “phenotype” to follow when developing new candidate fetal hemoglobin inducers or titrating hydroxyurea in treated sickle cell patients.

[1]  S. Newhouse,et al.  g(HbF): a genetic model of fetal hemoglobin in sickle cell disease. , 2018, Blood advances.

[2]  P. Sebastiani,et al.  Genetic determinants of HbF in Saudi Arabian and African Benin haplotype sickle cell anemia , 2017, American journal of hematology.

[3]  Paula J. Griffin,et al.  Sickle cell disease in Saudi Arabia: the phenotype in adults with the Arab‐Indian haplotype is not benign , 2014, British journal of haematology.

[4]  Paola Sebastiani,et al.  Fetal hemoglobin in sickle cell anemia: a glass half full? , 2013, Blood.

[5]  Matthew C. Canver,et al.  An Erythroid Enhancer of BCL11A Subject to Genetic Variation Determines Fetal Hemoglobin Level , 2013, Science.

[6]  S. Hay,et al.  Global Burden of Sickle Cell Anaemia in Children under Five, 2010–2050: Modelling Based on Demographics, Excess Mortality, and Interventions , 2013, PLoS medicine.

[7]  P. Sebastiani,et al.  Fetal hemoglobin in sickle cell anemia: genetic studies of the Arab-Indian haplotype. , 2013, Blood cells, molecules & diseases.

[8]  P. Sebastiani,et al.  Genetic modifiers of sickle cell disease , 2012, American journal of hematology.

[9]  B. Kumpel,et al.  Comparison of haemoglobin F detection by the acid elution test, flow cytometry and high‐performance liquid chromatography in maternal blood samples analysed for fetomaternal haemorrhage , 2012, Transfusion medicine.

[10]  P. Mehta.  Disorders of Hemoglobin: Genetics, Pathophysiology, and Clinical Management , 2012 .

[11]  I. Bhan,et al.  Fetal haemoglobin levels and haematological characteristics of compound heterozygotes for haemoglobin S and deletional hereditary persistence of fetal haemoglobin , 2012, British journal of haematology.

[12]  Cong Peng,et al.  Correction of Sickle Cell Disease in Adult Mice by Interference with Fetal Hemoglobin Silencing , 2011, Science.

[13]  Paola Sebastiani,et al.  Fetal hemoglobin in sickle cell anemia. , 2011, Blood.

[14]  R. Ware,et al.  Hydroxyurea for sickle cell anemia: what have we learned and what questions still remain? , 2011, Current opinion in hematology.

[15]  Joel N Hirschhorn,et al.  Fine-mapping at three loci known to affect fetal hemoglobin levels explains additional genetic variation , 2010, Nature Genetics.

[16]  R. Ware.  How I use hydroxyurea to treat young patients with sickle cell anemia. , 2010, Blood.

[17]  S. Orkin,et al.  Advances in the understanding of haemoglobin switching , 2010, British journal of haematology.

[18]  Stephen W. Hartley,et al.  Fetal hemoglobin in sickle cell anemia: genome-wide association studies suggest a regulatory region in the 5' olfactory receptor gene cluster. , 2010, Blood.

[19]  A. Hartzema,et al.  The cost of health care for children and adults with sickle cell disease , 2009, American journal of hematology.

[20]  D. Mohanty,et al.  Evaluation of F cells in sickle cell disorders by flow cytometry – comparison with the Kleihauer–Betke's slide method , 2007, International journal of laboratory hematology.

[21]  Stephen French,et al.  Essential haematology , 2004, BMJ.

[22]  M. Steinberg.  Therapies to increase fetal hemoglobin in sickle cell disease. , 2003, Current hematology reports.

[23]  B. Davis,et al.  Flow cytometric method for simultaneous assay of foetal haemoglobin containing red cells, reticulocytes and foetal haemoglobin containing reticulocytes. , 2001, Clinical and laboratory haematology.

[24]  M L Terrin,et al.  Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Multicenter Study of Hydroxyurea. , 1997, Blood.

[25]  H. Kamma,et al.  Estimation of fetal hemoglobin levels in individual red cells via fluorescence image cytometry. , 1995, Cytometry.

[26]  J. Hofrichter,et al.  The biophysics of sickle cell hydroxyurea therapy. , 1995, Science.

[27]  A. Schechter,et al.  Variation in fetal hemoglobin parameters and predicted hemoglobin S polymerization in sickle cell children in the first two years of life: Parisian Prospective Study on Sickle Cell Disease. , 1994, Blood.

[28]  O. Platt,et al.  Mortality in sickle cell disease. Life expectancy and risk factors for early death. , 1994, The New England journal of medicine.

[29]  A. Schechter,et al.  Sickle cell disease pathophysiology. , 1993, Bailliere's clinical haematology.

[30]  J. Hofrichter,et al.  Hemoglobin S gelation and sickle cell disease. , 1987, Blood.

[31]  S. Orkin,et al.  Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia. , 1984, The Journal of clinical investigation.

[32]  G. Dover,et al.  Hemoglobin determinations in single cells: Comparison of different techniques. , 1981, Progress in clinical and biological research.